Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focusing on the development and marketing of innovative pharmaceutical products for the treatment of mitochondrial and neuromuscular diseases. This area of high unmet medical need includes many orphan and niche indications with no current therapy.
Santhera strategically focuses on the development of Raxone®/Catena® (INN: idebenone). In Europe, Santhera plans to re-submit a marketing authorisation application for Raxone® as potentially first treatment for Leber’s Hereditary Optic Neuropathy (LHON). The product is also being investigated in Duchenne Muscular Dystrophy (Phase III), Primary Progressive Multiple Sclerosis (Phase II) and MELAS syndrome (Phase IIa).
The second compound in the clinical pipeline is omigapil for the treatment of Congenital Muscular Dystrophies.
Fipamezole, which successfully passed a Phase IIb study in treatment of Dyskinesia in Parkinson's Disease is available for partnering.